Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SRSD107
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sirius Shares Promising Phase 1 Data for Factor XI siRNA in Thromboembolic Disorders
Details : SRSD107 is a Factor XI inhibitor siRNA drug candidate, which is currently being evaluated for the treatment of thromboembolic disorders.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Not Applicable
December 10, 2024
Lead Product(s) : SRSD107
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SRSD107
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA
Details : SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). it specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/an...
Product Name : SRSD107
Product Type : Large molecule
Upfront Cash : Not Applicable
November 09, 2023
Lead Product(s) : SRSD107
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?